Holger Bronger

5PUBLICATIONS
19CO-AUTHORS
Predictive and prognostic markersMolecular targetsRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 24, 2026
High uPAR and Low miR-221 Expression Predict Poor Disease-Free Survival in Triple-Negative Breast Cancer.

|Jun 27, 2025
PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer.

Christoph Stange, Tobias F Dreyer, Maximilian Riedel

|Aug 12, 2023
Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients.

Fabian Stögbauer, Barbara Geß, Christine Brambs

|Sep 07, 2022
Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity.

Gökhan Güner, Marlene Aßfalg, Kai Zhao

|Mar 22, 2022
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.

Stefanie Seitz, Tobias F Dreyer, Christoph Stange

Pageof 1

Frequent Collaborators

3 joint publications

Marion Kiechle

1 joint publications

Katja Steiger

1 joint publications

Axel Imhof

1 joint publications

Georg Jocher